Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance and long-term extension study in Crohn's disease
NL-OMON54770Phase 3Recruiting
- Sponsor
- Site Management & Monitoring
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (5 arms), sponsored by Site Management & Monitoring. Primary endpoints: Clinical remission by daily stool frequency and abdominal pain score at Week 52 and Endoscopic response at Week 52. Started Apr 2019; status: recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON54770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54770.